anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hepatitis B virus (HBV) infection is a major public health problem. After HBV infection, viral antigens shift the immune balance in favor of viral escape. Sulforaphane (SFN) is a traditional Chinese medicine.It regulates multi-biological activities, including anti-inflammation, anticancer, and antiviral. However, few studies reported that SFN can inhibit HBV infection before.
METHODS: An immunocompetent HBV CBA/CaJ mouse model and a co-culture model were used to explore the effect of SFN on HBV and whether SFN altered the immune balance after HBV infection.
RESULTS: We found that SFN was able to reduce HBV DNA, cccDNA, HBsAg, HBeAg, and HBcAg levels in serum and liver tissues of HBV-infected mice. In vitro and in vivo experiments showed that SFN could significantly increase the expression of Cd86 and iNOS and inhibit the expression of Arg1 on macrophages after HBV infection. After SFN administration, Th17 markers in liver tissue and serum were significantly increased. There was no significant changes in the proportion of Treg cells in peripheral blood, but a significant increase in the proportion of Th17 cells and decrease of the Treg/Th17 ratio. Using a network pharmacology approach, we predicted macrophage migration inhibitory factor (MIF) as a potential target of SFN and further validated that MIF expression was significantly increased after HBV infection and SFN significantly inhibited MIF expression both in vitro and in vivo. There was an upward trend in HBV markers (p>0.05) after MIF overexpression. Overexpression of MIF combined with the use of SFN resulted in a significant reversion in the expression of HBV markers and polarization of macrophages towards the M1 phenotype.
CONCLUSION: Our results indicated that immunocompetent HBV CBA/CaJ mouse model is a good model to evaluate HBV infection. SFN could inhibit the expression of HBV markers, promote polarization of macrophages towards the M1 phenotype after HBV infection, change the proportion of Treg and Th17 cells. Our findings demonstrate that SFN inhibit HBV infection by inhibiting the expression of MIF and promoting the polarization of macrophages towards the M1 phenotype, which illustrates a promising therapeutic approach in HBV infection.
ABSTRACT In the management of disease, treatment with my new anti-HIV-virus drug will replace treatments being given with antibiotics, radiation, surgery, chemotherapy, etc. My drug will provide complete recovery, depending upon the duration of the illness, and the amount of damage already done to the body tissues. The drug destroys viruseswithout harming body cells. All biochemical processes going on in the cells are returned to normal. Full recovery will occur between 5 days and 3 years, depending upon the duration of the illness. The aggressive HIV-virus and its related viruses will not be bent on human destruction. The anti-HIV-virus drug will reduce and eliminate a number of diseases and it has no side effects. Many HIV viral infections will be cured by my anti-HIV-virus drug that will enable the cells to have normal biochemical processes.          Medicine Hat          March 2, 1992
Diarrhea occurred in 77% of 74 pediatric patients who received KOSELUGO in SPRINT, including Grade 3 in 15% of patients. Diarrhea resulting in permanent discontinuation occurred in 1.4% of patients. Diarrhea resulting in dose interruption or dose reduction occurred in 15% and 1.4% of patients, respectively. The median time to first onset of diarrhea was 17 days and the median duration was 2 days.

Serious gastrointestinal toxicities, including perforation, colitis, ileus, and intestinal obstruction, occurred in an unapproved population of adult patients with multiple tumor types who received KOSELUGO as a single agent or in combination with other anti-cancer agents. Colitis occurred in an unapproved population of pediatric patients with multiple tumor types who received KOSELUGO as a single agent.

Advise patients to start an anti-diarrheal agent (e.g., loperamide) immediately after the first episode of unformed, loose stool and to increase fluid intake during diarrhea episodes. Withhold, reduce dose, or permanently discontinue KOSELUGO based on severity of adverse reaction [see Dosage and Administration (2.2)].
Patients receive oxaliplatin IV over 2 hours, leucovorin IV over 2 hours, fluorouracil slow IV push over 2-4 minutes followed by continuous infusion over 46 hours on days 1 and 15. Patients also receive dasatinib PO QD on days 14, 15, and 28 of cycle 1 and day 1 of cycle 2. Patients may receive bevacizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to cycle 3 day 1 in the absence of disease progression or unacceptable toxicity.
In general, the DPPH and ORP methods are used to obtain extracts, and these methods have been used to measure and evaluate antioxidant effects. By confirming high values as measured by these two methods, the antioxidant effects of Cephalotaxus and Polygonatum can be confirmed. The DPPH method is a method that takes measurements by converting a percentage of a value obtained from a decrease in absorption strength at a wavelength of 517 nm as diphenylpicrylhydrazyl (free radicals) converts to diphenylpicrylhydrazine (non-radical) by reacting with a sample of traditional medicine material. That is, the DPPH method is a method of measuring an antioxidant effect indirectly by measuring a degree of decrease in radicals with a spectrophotometer. In particular, as the radicals change in color from purple to yellow due to the sample of traditional medicine material which is an antioxidant material, a decrease thereof is measured. The ORP method typically targets a value at 390 mV, and when this value is either stable or increased, it can be interpreted as that the sample of traditional medicine material has a good antioxidant reaction. In particular, the ORP method is a method using the amount of oxygen produced. In other words, if the amount of oxygen in the sample decreases, the ORP value decreases. Therefore, it can be said that if the antioxidant reaction of the sample is not good, the ORP thereof also decreases.
The dysregulation of N6-methyladenosine (m6A) RNA modification is widely recognized for its crucial roles in various diseases, including pulmonary hypertension (PH). Prior studies have highlighted the significant role of methyltransferase-like 3 (METTL3) in the pathogenesis of PH. Nevertheless, the potential and underlying mechanisms of METTL3 and its inhibitors as targets for PH treatment require further elucidation. In this study, increased levels of METTL3 were observed in various rodent models of PH. In vitro studies revealed that METTL3 silencing or treatment with STM2457, a specific METTL3 inhibitor, attenuated the proliferation and migration of pulmonary artery smooth muscle cells stimulated by platelet-derived growth factor-BB or hypoxia. Moreover, in vivo experiments using adeno-associated virus 9-mediated METTL3 silencing or STM2457 inhibition demonstrated improvement in SU5416/hypoxia-induced PH in mice. Additionally, m6A RNA immunoprecipitation analysis identified recombination signal binding protein for immunoglobulin kappa J region (RBPJ) regulated by METTL3 in rodent models of PH. Loss-of-function studies showed that silencing RBPJ could attenuate the changes in the proliferation and migration of pulmonary artery smooth muscle cells induced by platelet-derived growth factor-BB or hypoxia. Further studies indicated that METTL3 and YTH N6-methyladenosine RNA binding protein F1 (YTHDF1) regulated RBPJ mRNA expression in an m6A-dependent manner. These findings indicated that targeting METTL3 may be a promising therapeutic strategy for treating PH, and modulation of RBPJ could offer a potential intervention mechanism.
PCT No. PCT/EP95/03212 Sec. 371 Date Feb. 19, 1997 Sec. 102(e) Date Feb. 19, 1997 PCT Filed Aug. 14, 1995 PCT Pub. No. WO96/05837 PCT Pub. Date Feb. 29, 1996The invention relates to the use of N-substituted phenothiazines for the production of medicaments for the treatment of cerebral disorders. The invention likewise relates to novel active compounds which are prepared by reaction of phenothiazine with the appropriate acids, esters or amides or by reaction of the phenothiazinecarbonyl halides with amines. The active compounds are particularly suitable for the treatment of dementias and age-related leaning and memory disorders and depressions.
BACKGROUND: Acute cellular rejection (ACR) in heart transplant (HTx) recipients may be accompanied by cardiac cell damage with subsequent exposure to cardiac autoantigens and the production of cardiac autoantibodies (aABs). This study aimed to evaluate a peptide array screening approach for cardiac aABs in HTx recipients during ACR (ACR-HTx).
METHODS: In this retrospective single-center observational study, sera from 37 HTx recipients, as well as age and sex-matched healthy subjects were screened for a total of 130 cardiac aABs of partially overlapping peptide sequences directed against structural proteins using a peptide array approach.
RESULTS: In ACR-HTx, troponin I (TnI) serum levels were found to be elevated. Here, we could identify aABs against beta-2-adrenergic receptor (β-2AR: EAINCYANETCCDFFTNQAY) to be upregulated in ACR-HTx (intensities: 0.80 versus 1.31, P = 0.0413). Likewise, patients positive for β-2AR aABs showed higher TnI serum levels during ACR compared with aAB negative patients (10.0 versus 30.0 ng/L, P = 0.0375). Surprisingly, aABs against a sequence of troponin I (TnI: QKIFDLRGKFKRPTLRRV) were found to be downregulated in ACR-HTx (intensities: 3.49 versus 1.13, P = 0.0025). A comparison in healthy subjects showed the same TnI sequence to be upregulated in non-ACR-HTx (intensities: 2.19 versus 3.49, P = 0.0205), whereas the majority of aABs were suppressed in non-ACR-HTx.
CONCLUSIONS: Our study served as a feasibility analysis for a peptide array screening approach in HTx recipients during ACR and identified 2 different regulated aABs in ACR-HTx. Hence, further multicenter studies are needed to evaluate the prognostic implications of aAB testing and diagnostic or therapeutic consequences.
The musical content is composed by an algorithm (named "Melomics-Health") with the purpose of acting psychologically and physiologically on the person: the music follows a constant, melodic trend with a reduced musical density; time is unchanged and there are no significant dynamic and tonal variations. Patients will undergo to music listening for 15 minutes (5 tracks lasting 3 minutes each) before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context.
Half of the participants will be randomly assigned to the intervention group and will receive a three-month supply of phthalate- and bisphenol-free baby products (e.g., wipes, diaper cream) and a subscription to a cloth diaper service. Participants will be contacted after 2 and 6 weeks over the phone and administered a brief adherence survey.
PURPOSE: To obtain a compsn. for a chewing gum and the like which gives refreshing feeling of breath without bitter taste and can hold this effect for a long time by incorporating a carboxyamide expressed by a specified structural formula, gum base, sweetener and menthol. CONSTITUTION: This compsn. contains a gum base, sweetener, menthol and N-substd.-p-menthanecarboxyamide (preferably N-ethyl-p-menthane-3- carboxyamide) expressed by the formula. In the formula, R1 is H or an aliphatic group having up to 25 carbon atoms, R2 is hydroxy or an aliphatic group having up to 25 carbon atoms, and when R1 is H, R2 is an aryl, substd. phenyl, phenalkyl, (substd.) naphthyl, or pyridyl group with up to 10 carbon atoms, and when R1 is the same as R2 , they are (hetero)cyclic groups having up to 25 carbon atoms. It is preferable to use the amide by about 30 to 95wt.% and menthol by about 5 to 70% based on the weight of the compsn.
FIELD: veterinary science. SUBSTANCE: serum can be used for making passive immunity in pigs against hemophilosis, streptococcosis and pasteurellosis simultaneously. Antigens: cultures of Pasteurella multocida, serovara A, strain 1231, serovara B, strain 681 and serovara D, strain T-80 at amount 645-1 000 billion cells and additionally Haemophilus pleuropneumoniae, serovara-I, strain GU-19 and serovara-II, strain 5870 at amount 800-1000 billion cells, Streptococcus suis, serovara-2, strain Casly at amount 1000-1255 billion cells. To make ground-immunity inactivated concentrated pasteurellosis antigen is administrated to pigs twice subcutaneously in different body sites at dose 1-2 billion cells and also inactivated concentrated hemophilosis antigen at dose 2-3 billion cells, inactivated concentrated streptococcal antigen at dose 3-4 billion cells and repeatedly in 21 day 2-4 billion cells of pasteurellosis antigen, 4-6 billion cells of hemophilosis antigen and 6-8 billion cells of streptococcal antigen are administrated. Hyperimmunization is carried out with inactivated concentrated pasteurellosis, hemophilosis and streptococcal antigens 8-10-fold at 2-3 days interval. EFFECT: improved method of serum preparing. 1 tbl, 5 ex
PURPOSE:To use a dental etching agent having thixotropic properties, by sealing up the dental etching agent with a solid having specific physical properties in a small-sized bottle container, having a specified caliber, and changing the dental etching agent from a gel state into a sol state by shaking. CONSTITUTION:A dental etching agent having thixotropic properties and one or plural solids are sealed up in a small-sized bottle container, consisting of a fracture-resistant material, and having a small hole with 0.5-2.5mm. caliber. The above-mentioned solids are inert to the dental etching agent, and has a specific gravity of 1.5 times or more of that of the etching agent and is larger than the small hole of the container. The specific gravity of one solid is >=0.03g, and the total of the volumes must be 1/2 or less of the container volume. A spherical ceramic or metal coated with an acid-resistant substance is preferred for the solids. The etching agent having <=2.4X10<5>cP at 0.85/sec shear rate and <=6.0X 10<4>cP (25 deg.C) at 6.8/sec shear rate after allowing to stand for 2 weeks or more from the preparation thereof, is used.
BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) is carving out an increasing role in the treatment of esophageal neoplasia in the Western world. Contrary to Asia, most esophageal cancers in North America are associated with Barrett's esophagus. Patients with circumferential advanced neoplasia were previously managed by esophagectomy, but an increased experience with ESD has allowed for an endoscopic alternative. We present our experience with complete circumferential esophageal ESD at a North American referral center.
METHODS: All patients undergoing 100% circumferential esophageal ESD between October 2016 and January 2023 at a single tertiary care center in Canada were included in the cohort. Demographics, procedural data, and lesion characteristics are presented in this series.
RESULTS: Eleven patients underwent 100% circumferential esophageal ESD during this period for Barrett's neoplasia. All patients had technically successful procedures with en-bloc resection. Nine patients (82%) had R0 resections, defined as clear lateral and deep margins on histologic examination. Two patients had positive deep margins on histologic examination and proceeded to esophagectomy. Seven patients (64%) had adenocarcinoma on the final pathology, of which 6 (86%) had upstaging from their initial biopsy sampling results. The median area of resected specimen was 48 cm2 (interquartile range [IQR], 26-80), and the median procedure time was 231 minutes (IQR, 180-246). Procedural efficiency was 4.0 min/cm2 (IQR, 2.7-5). Two patients (18%) developed refractory strictures after the procedure, which were endoscopically managed to resolution.
CONCLUSIONS: Multifocal dysplastic Barrett's esophagus remains a challenging entity to treat. Circumferential ESD is a possible therapeutic option, with high procedural success and a low rate of adverse outcomes. This should be balanced against the risk of stricture development, as the optimal postprocedural prophylaxis regimen is investigated.
SCLC participants will receive MK-6070 via IV infusion Q2W during each 42-day cycle and I-DXd via IV infusion Q3W on Day 1 and Day 22 of each 42-day cycle. Dose escalation may continue until one or more RDEs are identified, participant discontinuation, or the Sponsor decides to stop enrollment.
INTRODUCTION: There have been concerns around the use of synthetic mesh for stress urinary incontinence (SUI) surgery with a renewed interest in the use of autologous tissues. Recently, an autologous transobturator sling (aTOT) has been described, but the comparative data with synthetic transobturator sling (sTOT) is limited. The objective of this systematic review and meta-analysis was to assess the outcome of aTOT and compare it with sTOT.
METHODS: A systematic search of PubMed, Scopus, and Web of Science databases was performed and all articles available up to December 31, 2023 were screened. Studies reporting on the outcomes of aTOT and those comparing aTOT with sTOT were included. This review was performed as per Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.
RESULTS: Eleven studies evaluating 323 patients that met the criteria were included in the final analysis, of which 6 were single arm (155 patients) and 5 were comparative. In single-arm studies, the pooled success rate, defined as negative cough stress test at 12 months follow-up was 96.8%, 3.8% had postoperative urinary retention, 6.1% had graft site-related complications and 7.6% required additional intervention for persistent SUI. The overall complication rate was 20.6% and there were no Clavien III-V complications. aTOT had similar success and complication rates when compared with sTOT but had a significantly longer operative time (weighted mean difference: 22.35 min, p < 0.00001) and superior sexual function outcomes.
CONCLUSIONS: aTOT, at short-term follow-up (12 months), has similar efficacy and complication rates when compared to sTOT. However, given that the data is limited and not of very good quality, and the fact that long-term follow-up is not available, further studies are required to better define the role of aTOT in the management of female patients with SUI.
PURPOSE: A double-specific gene expression system for a neuroglial tissue and an ischemic tissue is provided to simultaneously recognize the tissues and to effectively treat or prevent ischemic cerebral diseases. CONSTITUTION: A double-specific recombinant vector for a neuroglial tissue and an ischemic tissue contains etythropoietin enhancer, nestin intron, promoter, and therapeutic agent for ischemic cerebral diseases. The enhancer contains a base of sequence number 1. The netin intron contains a base of sequence number 2. The promoter has an ischemic tissue-selective promoter sequence. The recombinant vector is a viral vector. A pharmaceutical composition for treating ischemic cerebral diseases contains the recombinant vector as an active ingredient.
Vascular calcification is a common accompanying pathological change in many chronic diseases, which is caused by calcium deposition in the blood vessel wall and leads to abnormal blood vessel function. With the progress of medical technology, the diagnosis rate of vascular calcification has explosively increased. However, due to its mechanism's complexity, no effective drug can relieve or even reverse vascular calcification. Irisin is a myogenic cytokine regulating adipose tissue browning, energy metabolism, glucose metabolism, and other physiological processes. Previous studies have shown that irisin could serve as a predictor for vascular calcification, and protect against hypertension, diabetes, chronic kidney disease, and other risk factors for vascular calcification. In terms of mechanism, it improves vascular endothelial dysfunction and phenotypic transformation of vascular smooth muscle cells. All the above evidence suggests that irisin plays a predictive and protective role in vascular calcification. In this review, we summarize the association of irisin to the related risk factors for vascular calcification and mainly explore the role of irisin in vascular calcification.
This cohort will include 450 patients at the time of transplantation. The following number of participants will be enrolled in the cohort according to strata defined by organ-transplanted type and baseline immune status.
Metopirone may induce acute adrenal insufficiency in patients with reduced adrenal secretory capacity, as well as in patients with global pituitary insufficiency. The test should be performed in the hospital with close monitoring in case of suspected adrenal insufficiency.

Ability of adrenals to respond to exogenous ACTH should be demonstrated before Metopirone is employed as a test. 

In the presence of hypo‑ or hyperthyroidism, response to the Metopirone test may be subnormal.

If adrenocortical or anterior pituitary function is more severely compromised than indicated by the results of the test, Metopirone may trigger adrenal insufficiency. This can be corrected by giving appropriate doses of corticosteroids.
Papillary microcarcinomas (PMCs) are papillary carcinomas ≤1 cm in size, with an increasing incidence. Although generally indolent, some cases exhibit aggressive behavior. Recently, active surveillance has been recommended to avoid surgical treatment. Identifying molecular changes that predict aggressiveness in PMCs has gained importance, but studies are limited. We aimed to demonstrate TERT expression and BRAF V600E positivity immunohistochemically in PMCs and correlate them with histomorphological features, subtypes, and clinicopathological findings. We included 95 PMC cases diagnosed between 2010 and 2019 at the Department of Pathology, Faculty of Medicine, XXX University. We investigated TERT expression using RT-PCR. We evaluated BRAF V600E mutation immunohistochemically. We evaluated the relationship between genetic, histomorphological, and clinicopathological findings. In patients with multifocality and those with a tumor size ≥0.5 cm, the frequency of lymph node metastasis was significantly higher. A positive correlation was shown between BRAF V600E positivity and lymph node metastasis, lymphovascular invasion, advanced disease stage, and classical subtype by univariate analyses. We detected TERT expression in 18 of 95 patients (7.8 %). No relationship could be detected between TERT expression alone or combined with BRAF positivity and clinicopathological features. Although TERT mutations are associated with aggressiveness in thyroid cancers, this association was absent in PMCs. The presence of TERT expression was demonstrated in some cases. However, TERT expression could not be associated with clinicopathological findings, which is consistent with the literature suggesting that TERT plays a role in advanced stages of carcinogenesis.